Concept · Learn
What Are Neuropeptides? Plain-English Guide
What are neuropeptides? Neuropeptides are signaling peptides made and released by neurons. They act less like a split-second electrical switch and more like a longer-running adjustment dial, changing pain, appetite, stress, mood, and other circuits. Native examples have established biology; popular synthetic brain peptides such as Semax and Selank have much thinner clinical proof.
What is the neuropeptide definition?
The strict neuropeptide definition is a short amino-acid chain that a neuron makes, stores, and releases to signal other cells. “Made by neurons” is the useful dividing line. Neuropeptides can act in the brain, peripheral nerves, or elsewhere in the body.
Neurons build neuropeptides as larger precursor proteins in the cell body. Enzymes cut them into active pieces, which travel in dense-core vesicles toward release sites. A peer-reviewed overview of neuropeptide biology maps that process and their wider diffusion to cell-surface receptors.
“Brain peptides” is a broader retail and research label. Some are natural neuropeptides; others are synthetic molecules aimed at brain-related outcomes. The labels overlap, but they are not synonyms.
What is the difference between a neuropeptide and a neurotransmitter?
The neuropeptide vs neurotransmitter distinction is mostly about chemistry and signaling style, not two sealed categories. A neuropeptide can function as a neurotransmitter. Compared with classic small-molecule transmitters such as glutamate or gamma-aminobutyric acid (GABA), peptide signals are generally made differently, released from different vesicles, cleared more slowly, and used for longer modulation.
| Feature | Neuropeptides | Classic neurotransmitters |
|---|---|---|
| Material | Short amino-acid chains | Usually small molecules |
| Where made | Mainly in the neuron’s cell body as larger precursors | Often made or replenished near nerve endings |
| Typical receptor | Usually G-protein-coupled receptors | Often fast ion-channel receptors; some use slower receptors |
| Typical effect | Slower onset, longer modulation, wider reach | Often rapid, point-to-point signaling |
| After release | Broken down by enzymes; generally not taken back up intact | Often rapidly cleared or recycled by reuptake |
Neuropeptides and classic transmitters often leave the same neuron together. The transmitter delivers the quick message; the peptide changes its strength and duration. Think doorbell plus dimmer switch, not rival systems.
How do neuropeptides work in the brain and body?
Neuropeptides work by binding receptor types that recognize particular peptide shapes, then changing activity inside the target cell. Most use G-protein-coupled receptors, which trigger a chain of intracellular steps rather than opening a fast electrical channel directly. That helps explain why many peptide effects build more slowly and outlast the initial neuronal firing.
“Receptor-specific” does not mean one peptide has one simple job. Release location, receptor subtype, tissue, concentration, and co-released transmitters all matter. A brain peptide may also signal in the gut, blood vessels, or immune system.
A mechanism cannot prove a treatment claim. Receptor binding or a changed mouse circuit establishes plausibility; meaningful improvement in people requires a human study.
What are some neuropeptide examples?
Neuropeptide examples include neuropeptide Y, substance P, calcitonin gene-related peptide (CGRP), oxytocin, vasopressin, endorphins, enkephalins, and vasoactive intestinal peptide (VIP). These signals help regulate overlapping functions including appetite, pain, stress, social behavior, blood-vessel tone, digestion, and hormone release. No single “neuropeptide effect” covers the family.
CGRP offers a clean evidence lesson: its migraine biology led to approved drugs that block CGRP signaling. That success does not validate unrelated brain peptides. Evidence belongs to the exact molecule and use.
VIP is another useful example. VIP is a natural 28-amino-acid neuropeptide made in central and peripheral nerves. VIP has substantial human physiology and clinical research, yet its popular intranasal “recovery” use still lacks controlled human evidence. A deep literature can coexist with an unproven specific claim.
Are Semax and Selank natural neuropeptides?
Semax and Selank are better described as synthetic neuroactive peptides than as natural neuropeptides. Semax is a seven-amino-acid analog derived from a fragment of adrenocorticotropic hormone (ACTH). Selank is a seven-amino-acid analog based on tuftsin. Neurons do not naturally make either finished sequence as a native messenger.
Both fit the broader nootropic peptide hub because people research them for cognition, neuroprotection, anxiety, and stress. That category describes intended use, not biological origin.
Semax has Russian clinical papers going back to the 1990s. One 1997 comparative stroke study included 30 Semax-treated patients and 80 controls. A 2008 Selank study compared 30 patients receiving Selank with 32 receiving medazepam. Those are human findings, not rodent findings.
How strong is the evidence for Semax and Selank?
Semax and Selank carry decades of Russian clinical research and use, but thin Western trial evidence. The honest grade is not “nothing,” and it is not “settled.” The published human studies are small, often Russian-language, concentrated among related research groups, and not backed by the large, independently replicated Western programs expected for broad clinical confidence.
| Claim | Best honest reading |
|---|---|
| Semax for acute stroke recovery | Small human comparative studies; not enough for a general efficacy claim |
| Semax for focus in healthy adults | Mostly animal and mechanism evidence; human benefit remains unestablished |
| Selank for diagnosed anxiety | Small Russian human trials report benefit; independent replication is thin |
| Selank for healthy-person cognitive enhancement | Mechanistic or anecdotal, not established by controlled human trials |
| VIP for general “recovery” | Native biology and other human research exist; this specific use remains untested |
This claim-by-claim grading matters more than calling a whole compound “human proven.” The evidence-grading guide keeps a receptor result, a rat result, a small clinical comparison, and a replicated randomized trial on separate rungs.
Are nootropic brain peptides FDA-approved?
Semax and Selank are not FDA-approved drugs in the United States, and FDA has flagged safety-information and quality concerns around compounded versions. FDA’s current compounding page says Semax may carry immunogenicity risks from aggregation or peptide-related impurities and that human safety information is limited; FDA says it also lacks important human safety information for compounded Selank acetate.
The 2026 picture is moving. In a May 2026 Semax briefing, FDA confirmed Russian registration but no FDA-approved drug component. FDA proposed against adding Semax free base or acetate to the 503A Bulks List, with committee discussion scheduled for July 24, 2026. That proposal is not a final determination.
The practical answer to “what are neuropeptides?” therefore needs two layers: native signaling biology is established, while a synthetic brain peptide’s clinical value must be proved for its exact use. Interesting chemistry does not get to skip that step.